DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the presentation of data from the Phase 2a trial of AGS-004, demonstrating that the personalized immunotherapy has a positive impact on the genetic diversity of residual HIV virus, and also results in substantially increased time to viral rebound in HIV patients treated with AGS-004 following antiretroviral therapy (ART) interruption. The data were discussed in an oral presentation at the 19th Annual Canadian Conference on HIV/AIDS Research (CAHR), held May 13-16, 2010 in Saskatoon, Saskatchewan. AGS-004 is a product of the Company’s Arcelis™ technology and is a personalized, RNA-loaded, dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden.
